LC
FIGURE 1 · Panel _A_
Panel _A_ 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Zhen Zhang, Xinchen Sun, Anwen Liu, Yaqun Zhu, Tao Zhang, Luying Liu, Jianhui Jia, Shisheng Tan, Junxin Wu, Xin Wang, Juying Zhou, Jialin Yang, Chen Zhang, Hongyan Zhang, Xinjia He, Gang Cai, Chengyi Huang, Fan Xia, Juefeng Wan, Hui Zhang, Lijun Shen, Ling Wang, Wei Zhang, Sanjun Cai, Ji Zhu
Cancer Commun (Lond) 45(11) 1417-1430
BACKGROUND: The optimal regimen and chemotherapy intensity are still under investigation for neoadjuvant treatment of locally advanced rectal cancer (LARC). The CinClare trial has demonstrated improved pathologic complete response (pCR) with the addition of irinotecan to neoadjuvant chemoradiotherapy (CRT) guided by uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotype in LARC. Here, we report the 5-year follow-up outcomes of the CinClare study. METHODS: From November 2015 to December 2017, this randomized, open-label, multicenter, phase III trial enrolled 360 patients with LARC and assigned them in a 1:1 ratio to CapIriRT (radiation with capecitabine combined with irinotecan followed by irinotecan and capecitabine) or CapRT (radiation with concurrent capecitabine followed by oxaliplatin and capecitabine). Irinotecan dosing was guided by UGT1A1 genotype (80 mg/m2 for *1/*1 and 65 mg/m2 for *1/*28). The endpoints, including local control (LC), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS), were analyzed using the log-rank test, Cox proportional hazards regression and restricted mean survival time (RMST) test at the data cut-off date of June 2023. RESULTS: With a median follow-up of 60 months, the CapIriRT group showed numerically higher 5-year LC (95.6% vs. 93.9%), 5-year DMFS (83.9% vs. 77.9%), 5-year DFS (77.7% vs. 70.6%), and 5-year OS rates (82.9% vs. 76.1%) than the CapRT group. Further RMST test also showed a statistically significant difference in DFS (P < 0.05) and a borderline difference in OS (P = 0.050). Among the UGT1A1 *1/*1 population, the CapIriRT group had significantly improved 5-year rates of DMFS, DFS, and OS (all P < 0.05). Patients achieving pCR also had significantly longer DFS and OS compared to non-pCR patients (P < 0.05). CONCLUSIONS: The addition of irinotecan guided by UGT1A1 genotype to a standard capecitabine-based scheme brings clinical benefits with improved LC, DMFS, DFS, and OS. Patients with the UGT1A1 *1/*1 genotype derived notable benefit from irinotecan, with improved survival outcomes. Achievement of pCR is crucial as it is associated with improved long-term survival. These findings support the integration of genomic testing into clinical practice to achieve a personalized irinotecan dosing regimen, which can optimize efficacy and safety. TRIAL REGISTRATION: ClinicalTrials.gov (NCT02605265).
4 个 Figure · 24 个 KM 面板
FIGURE 1 Long‐term survival outcomes in the mITT population ( n = 356). (A) Kaplan‐Meier curve of LC. The 5‐year LC rates were 95.6% and 93.9% in the CapIriRT and CapRT groups, respectively. (B) Kaplan‐Meier curve of DMFS. The 5‐year DMFS rates were 83.9% and 77.9% in the CapIriRT and CapRT groups, respectively. (C) Kaplan‐Meier curve of DFS. The 5‐year DFS rates were 77.7% and 70.6% in the CapIriRT and CapRT groups, respectively. (D) Kaplan‐Meier curve of OS. The 5‐year OS rates were 82.9% and 76.1% in the CapIriRT and CapRT groups, respectively. Abbreviations: CI, confidence interval; DFS, disease‐free survival; DMFS, distant metastasis‐free survival; HR, hazard ratio; LC, local control; mITT, modified intent‐to‐treat; OS, overall survival.
FIGURE 1 · Panel _A_
Panel _A_ 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 1 · Panel _B_
Panel _B_ 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 1 · Panel _C_
Panel _C_ 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 1 · Panel _D_
Panel _D_ 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 3 Long‐term survival outcomes stratified by UGT1A1 genotype. (A‐D) Kaplan‐Meier curves for LC, DMFS, DFS and OS of UGT1A1 *1/*1 subgroup, respectively. (E‐H) Kaplan‐Meier curves for LC, DMFS, DFS and OS of UGT1A1 *1/*28 subgroup, respectively. In the UGT1A1 *1/*1 subgroup, patients who received CapIriRT showed improved DMFS, DFS, and OS ( p < 0.05) compared to those who received CapRT, as well as a numerical advantage in LC. In the UGT1A1 *1/*28 genotype subgroup, no substantial differences were observed in LC, DMFS, DFS, and OS. Abbreviations: DFS, disease‐free survival; DMFS, distant metastasis‐free survival; LC, local control; OS, overall survival; UGT1A1, uridine diphosphate glucuronosyltransferase 1A1.
FIGURE 3 · Panel A
Panel A 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 3 · Panel B
Panel B 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 3 · Panel C
Panel C 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 3 · Panel D
Panel D 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 3 · Panel E
Panel E 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 3 · Panel F
Panel F 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 3 · Panel G
Panel G 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 3 · Panel H
Panel H 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 4 Survival outcomes stratified by pCR status in 311 patients who had undergone surgery in the mITT population. (A) Kaplan‐Meier curve of LC. (B) Kaplan‐Meier curve of DMFS. (C) Kaplan‐Meier curve of DFS. (D) Kaplan‐Meier curve of OS. In the mITT population, patients achieving pCR had longer DFS and OS compared to non‐pCR patients, as well as an improved trend for LC and DMFS. Abbreviations: DFS, disease‐free survival; DMFS, distant metastasis‐free survival; LC, local control; OS, overall survival; pCR, pathologic complete response.
FIGURE 4 · Panel A
Panel A 是同一 FIGURE 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 4 · Panel B
Panel B 是同一 FIGURE 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 4 · Panel C
Panel C 是同一 FIGURE 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 4 · Panel D
Panel D 是同一 FIGURE 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 5 Survival outcomes by pCR status in two treatment arms. (A‐D) Kaplan‐Meier curves for LC, DMFS, DFS and OS of the pCR subgroup, respectively. (E‐H) Kaplan‐Meier curves for LC, DMFS, DFS and OS of the non‐pCR subgroup, respectively. Among patients who achieved pCR, outcomes were similar between the CapIriRT and CapRT groups. However, among patients who did not achieve pCR, the CapIriRT group had slightly longer LC, DMFS, and DFS compared to the CapRT group. Abbreviations: DFS, disease‐free survival; DMFS, distant metastasis‐free survival; LC, local control; OS, overall survival; pCR, pathologic complete response.
FIGURE 5 · Panel _A_
Panel _A_ 是同一 FIGURE 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 5 · Panel _B_
Panel _B_ 是同一 FIGURE 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 5 · Panel _C_
Panel _C_ 是同一 FIGURE 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 5 · Panel _D_
Panel _D_ 是同一 FIGURE 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 5 · Panel _E_
Panel _E_ 是同一 FIGURE 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 5 · Panel _F_
Panel _F_ 是同一 FIGURE 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 5 · Panel _G_
Panel _G_ 是同一 FIGURE 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 5 · Panel _H_
Panel _H_ 是同一 FIGURE 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。